MedPath

OSAKA METROPOLITAN UNIVERSITY

🇯🇵Japan
Ownership
-
Established
2022-01-01
Employees
-
Market Cap
-
Website
https://www.omu.ac.jp/

Clinical Trials

31

Active:1
Completed:12

Trial Phases

1 Phases

Not Applicable:25

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials

Not Applicable
25 (100.0%)

Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part2)

Conditions
Monkeypox (Mpox)
First Posted Date
2025-07-16
Last Posted Date
2025-07-16
Lead Sponsor
Osaka Metropolitan University
Target Recruit Count
122
Registration Number
NCT07067723
Locations
🇨🇩

Equateur Provincial Public Health Laboratory, Mbandaka, Equateur, Congo, The Democratic Republic of the

Epidemiological and Clinical Characteristics of Mpox Outbreak in Equateur, the DR Congo (Part1)

Conditions
Mpox (Monkeypox)
First Posted Date
2025-07-09
Last Posted Date
2025-07-09
Lead Sponsor
Osaka Metropolitan University
Target Recruit Count
122
Registration Number
NCT07055867
Locations
🇨🇩

Equateur Provincial Public Health Laboratory, Mbandaka, Equateur, Congo, The Democratic Republic of the

Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part3)

Conditions
Mpox (Monkeypox)
First Posted Date
2025-05-22
Last Posted Date
2025-05-29
Lead Sponsor
Osaka Metropolitan University
Target Recruit Count
144
Registration Number
NCT06984705
Locations
🇨🇩

Equateur Provincial Public Health Laboratory, Mbandaka, Equateur, Congo, The Democratic Republic of the

Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2

Recruiting
Conditions
Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes
Diabetes Mellitus
Hypertension
Hyperglycemia
Hyperlipidemia
Dyslipidemia
Hyperuricemia or Gout
Hyperuricemia, Gout
Obesity
First Posted Date
2024-11-19
Last Posted Date
2024-12-04
Lead Sponsor
Osaka Metropolitan University
Target Recruit Count
2000
Registration Number
NCT06694012
Locations
🇯🇵

The Ohtori Health Promotion Center, Sakai, Osaka, Japan

Polyethylene Wear Particle Analysis of THA

Recruiting
Conditions
Hip Arthropathy
Wear of Articular Bearing Surface of Prosthetic Joint
First Posted Date
2024-05-29
Last Posted Date
2025-01-20
Lead Sponsor
Osaka Metropolitan University
Target Recruit Count
90
Registration Number
NCT06432543
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇯🇵

Osaka Metropolitan University, Osaka, Japan

  • Prev
  • 1
  • 2
  • Next

News

Japanese Researchers Develop GAI-17, Novel Stroke Drug with Six-Hour Treatment Window

Researchers at Osaka Metropolitan University developed GAI-17, a novel stroke treatment that significantly reduces brain cell death and paralysis in animal models by inhibiting GAPDH protein aggregation.

Shionogi and Osaka Metropolitan University Form Strategic Alliance to Combat Infectious Diseases

Shionogi and Osaka Metropolitan University have established a comprehensive collaboration agreement focused on infectious disease research, diagnostics development, and public health system strengthening.

Canagliflozin Shows Promise in Protecting Kidney Health in Type 2 Diabetes Patients

A Japanese study explored the potential of SGLT2 inhibitors, particularly canagliflozin, in protecting kidney health in patients with type 2 diabetes.

Chinese Herbal Medicine Shows Promise in Restoring Cognitive Function in Dementia Models

Researchers found that Ziziphus jujuba Miller var. spinosa, a traditional Chinese medicine, restored cognitive and motor functions in dementia model mice.

BMI Thresholds Impact Mortality Risk in NSCLC Immunotherapy vs. Chemotherapy

A study of over 500,000 lung cancer patients reveals that BMI affects mortality risk differently in immunotherapy versus chemotherapy.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.